Live
- HYDRAA Demolishes Illegal Shops in Manikonda’s Alkapur Colony Amid Protests
- Why Dates Are a Winter Superfood: Top Health Benefits of Khajoor
- District Judge Ganta Kavitha Devi Conducts Surprise Inspection at Gadwal Government School
- 120-Foot Asteroid 2024 XN1 to Safely Pass Earth on Christmas Eve: NASA
- CITU Demands Regularization of ANMs Without Written Exam
- Gadwal Bar Association Demands Relocation of Court Complex from Pooduru Site
- Keerthy Suresh Flaunts Mangalsutra in First Event After Wedding with Antony Thattil
- Ensure PM-KISAN Benefits Reach Eligible Farmers – Collector Badavath Santosh
- Strict Action Against Negligence in Midday Meal Implementation – Collector Badavath Santosh
- Avoid Answering Video Calls from Unknown Numbers – Cyber Crime DSP Girikumar
Pharma cos may report lower sales in Q2
Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17,\" Reliance Securities said in its report here. \"However, industry expects strong recovery in domestic formulations business for most companies under our
Mumbai: Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, a report said. "We expect the pharmaceutical companies to report subdued performance on sales, EBITDA and PAT front in Q2 FY17 led by the quiet US business on lack of fresh ANDA approvals due to the pending US FDA issues.
Pharma companies are likely to report sales, EBITDA and PAT growth of 10.2 per cent YoY, 9.4 per cent YoY and 14.3 per cent YoY, respectively in Q2 FY17," Reliance Securities said in its report here. "However, industry expects strong recovery in domestic formulations business for most companies under our coverage driven by strong monsoon, while favourable y-o-y movement in non-USD currencies and new drugs approvals will drive growth in emerging markets," the report said.
It said EBITDA margins will continue to be under pressure on account of increased R&D spending and adverse product-mix. "We continue to remain positive on long-term prospects of the pharma sector and recommend being stock-specific," it added. The US remains mainstay for most companies, contributing 55-60 per cent of total exports. Measures like aggressive R&D spend and scale-up in complex ANDA filings are considered to be the key re-rating triggers, it said. However, few operational metrics have exhibited lack of momentum like critical facilities under US FDA lens, channel consolidation and slowdown in approvals.
